Replies to post #413046 on Amarin Corp Plc (AMRN)

[couldbebetter]

Agreed! As we both understand Vascepa should (and still could) be a multi-billion
dollar drug even without the US. The problem that I see is that it is unlikely to happen
without BP having ownership. If Alex Denner can demonstrate to BP that they could
get Vascepa sales to the point of over $2 billion a year in revenues then they would
be justified in expecting a BO of $7-$9 billion. What bothers me is that what I see
as potentially massive new uses of Vascepa for Cancer and Alzheimer's disease
do not really seem to be on the radar screen. (I wish I had Alex Denner's thoughts
about these two prospective indications for Vascepa.) Of course, the CVD potential
by itself should justify a double digit BO price for AMRN. So pathetically sad that
a very safe and affordable medication that could literally benefit hundreds of
millions of people throughout the world cannot even muster a million users!